-
Pfizer gets FDA priority review for pneumonia vaccine
The FDA accepted Pfizer for a priority review of a supplemental Biologics License Application for its pneumococcal conjugate vaccine for children. -
Moderna, oncology drug company partner to broaden mRNA use
Moderna and CytomX Therapeutics, a cancer drug company, will collaborate to develop investigational mRNA-based therapies, the companies said Jan. 5. -
1st pediatric RSV drug could be approved before next viral season
The FDA accepted AstraZeneca and Sanofi's application for their pediatric respiratory syncytial virus drug Jan. 5, and if approved, it would be the first single-dose preventive option for a virus that infects nearly all children before the age of 2. -
Paxlovid use ebbs amid lack of funds, unclear rebound risk
Millions of Paxlovid packets haven't been used, which could be tied to COVID-19 rebound risks, less federal funds and diminishing public concern about the pandemic, according to an article published Jan. 3 in Nature. -
Walgreens, CVS plan to dispense abortion pills
After the FDA said it would allow some retail pharmacies to dispense prescribed abortion pills, Walgreens and CVS told Becker's they plan to distribute the drug mifepristone. -
Pediatric pain medication shortage delaying care: 5 updates
As retail pharmacy chains ration sales of children's pain medications amid a national shortage, some physicians are delaying operations as families scramble for medicine cabinet staples. -
10 systems seeking pharmacy leaders
The following 10 hospitals, health systems and hospital operators have posted job listings seeking pharmacy leaders in the last week. -
12 blood pressure drugs back-ordered, partly because of carcinogen
Three drugmakers each have four blood pressure drugs in short supply after some were recalled in 2022 because of the presence of nitrosamine, which the FDA has labeled as a "probable human carcinogen." -
Moderna to scoop up genomics company for $85M
Moderna is set to acquire OriCiro for $85 million. -
Rite Aid launches mini-pharmacy program to reduce 'pharmacy deserts'
Rite Aid is opening mini-locations in rural areas to help underserved communities and fight "pharmacy deserts," Retail Wire reported Jan. 3. -
UPMC, community college partner in pharmacy technician training program
Pittsburgh-based UPMC and HACC, Central Pennsylvania's Community College, are teaming up to bolster the community college's pharmacy technician training program. -
FDA clears abortion pills for retail pharmacies
Prescribed abortion pills can now be dispensed at retail pharmacies, according to an FDA decision published Jan. 3. -
Corewell Health moves pharmacy inside its hospital
Corewell Health, a system with dual headquarters in Grand Rapids and Southfield, Mich., moved a retail pharmacy into one of its hospitals Jan. 3. -
5 things to know about Eli Lilly's diabetes drug
Eli Lilly's experimental diabetes and weight-loss drug, tirzepatide, is projected to net between $25 billion and $48 billion in sales once it's approved, NBC News reported Jan. 1. -
Arizona files consumer fraud suit against drugmaker
Arizona's attorney general filed a lawsuit against RLC Labs, which makes prescription thyroid drug tablets, for consumer fraud with allegations of false or misleading statements. -
The remaining efficacy of omicron boosters: 5 studies
As researchers study how well the omicron-targeting boosters work against the now-dominant subvariant XBB.1.5, here's what five recent studies found: -
FDA approves expanded use of cancer drug Tecentriq
The FDA recently approved an immunotherapy drug called Tecentriq (atezolizumab) for patients ages 2 and up who have advanced alveolar soft part sarcoma that has spread to other parts of the body or cannot be removed by surgery, U.S. News & World Report reported Jan. 2. -
96 drugs lost exclusivity in 2022
In 2022, the FDA approved 96 first-time generic drugs. -
Baptist Health selects new pharmacy director
Baptist Health Floyd named Evan Hampton, PharmD, its pharmacy director, effective Jan. 1. -
Federal investigation blames FDA, Biogen for Aduhelm scandal
Murky documentation of meetings between Biogen and the FDA, plus an "unjustifiably high price" for a drug that lacked clinical data, are at fault for the Adulelm controversy, two House committees said Dec. 29 in a report.
Page 12 of 50